[Glucose-6-phosphate-dehydrogenase deficiency management in western countries. A literature review]

Semergen. 2020 Jan-Feb;46(1):68-74. doi: 10.1016/j.semerg.2019.05.010. Epub 2019 Jul 20.
[Article in Spanish]

Abstract

Glucose-6-phosphate-dehydrogenase (G6PD) deficiency is the most prevalent abnormal enzyme condition in the general population, but most patients are asymptomatic (crises are triggered by certain drugs or foods). The clinical consequences are greater in patients coming from endemic areas of malaria (antimalarial medication can trigger a crisis). The increase in migratory flows has led to an increase in the number of people affected by the deficiency in our practice, which makes it interesting to carry out a literature review of this condition. Some authors have communicated that patients with G6PD deficiency have an increase in prevalence of cardiovascular diseases, which requires the strict control of cardiovascular risk factors. However, these patients show a decrease in colorectal cancer prevalence. In addition, donations of bone marrow and haematopoietic derivatives could be performed safely.

Keywords: Atención Primaria; Deficiencia de glucosafosfato deshidrogenasa; Glucose-6-phosphate dehydrogenase deficiency; Immigration; Inmigración; Primary Health Care.

Publication types

  • Systematic Review

MeSH terms

  • Antimalarials / administration & dosage
  • Antimalarials / adverse effects*
  • Cardiovascular Diseases / epidemiology*
  • Glucosephosphate Dehydrogenase Deficiency / epidemiology*
  • Glucosephosphate Dehydrogenase Deficiency / etiology
  • Glucosephosphate Dehydrogenase Deficiency / therapy
  • Humans
  • Malaria / drug therapy
  • Malaria / epidemiology
  • Risk Factors

Substances

  • Antimalarials